21: Breaking Down Celebrate and POLY-HF: Two Paths to Better Cardiac Care

20: Inside AHA’s Late-Breaking Lipid Trials: The Rise of Oral PCSK9 Inhibition

19: Jazzed Up for American Heart Association 2025 in New Orleans

18: The Adipokine Hypothesis and Inflammation: Explaining Pathogenesis and Guiding Treatment

17: New Frontiers in Hypertension Care: Insights from the KARDIA-3 and Bax Hypertension Trials

16: Deconstructing Meta-Analyses From ESC 2025

15: ESC 2025 Highlights: Insights on ALONE-AF and AQUATIC Trials

14: Sifting Through Discordant Data From ESC 2025

13: From Guidelines to Action: Pharmacy’s Role in Hypertension Management

12: A New Joint Scientific Statement and What to Watch for at the European Society of Cardiology Congress 2025

11: A Roundtable Discussion of Upcoming Hot Line Trials at ESC Congress 2025

10: COBRRA Trial Results Raise Questions About VTE Management

9: An Overview of Intravenous Iron in Heart Failure and the FAIR-HF2 Trial

8: Concierge Pharmacy's Role in Cardio-Kidney-Metabolic Health Care

7: New Programs Aim to Improve Implementation of Cardiovascular Interventions

6: Pharmacist Involvement in Clinical Research and the FINEARTS-HF Trial

5: Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

4: The RIVAWAR Trial and ACS Guidelines for LV Thrombus

3: Updates to Acute Coronary Syndrome Guidelines

2: Everything You Need to Know from the American College of Cardiology 2025 Scientific Session